{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:38:26Z","timestamp":1794335906439,"version":"4.9.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cytomegalovirus (CMV) reactivation remains a common and serious complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), often leading to significant morbidity and mortality in immunocompromised recipients. Adoptive transfer of CMV-specific cytotoxic T lymphocytes (CMV-CTLs) has emerged as a promising immunotherapeutic approach to restore antiviral immunity and prevent CMV-related complications. This interim analysis of a randomized phase I\u2013II clinical trial evaluates the safety and preliminary efficacy of prophylactic infusion of donor-derived CMV-CTLs administered early after allo-HSCT. Twenty adult allo-HSCT recipients were randomized 1:1 to receive either standard care (control group) or a single intravenous infusion of 10 million donor-derived CMV-CTLs per m\n                    <jats:sup>2<\/jats:sup>\n                    of body surface area (intervention group) between days\u2009+\u200914 to\u2009+\u200921 post-transplant. The primary endpoint was safety, defined by infusion-related adverse events and incidence of acute graft-versus-host disease (aGvHD). Secondary endpoints included incidence and kinetics of CMV reactivation, measured by serial quantitative RT-PCR during the first 90\u00a0days post-transplant. Baseline characteristics were balanced between the two groups. No grade 3\u20135 adverse events were observed following CMV-CTL infusion. aGvHD grade II occurred in 30% of the intervention group versus 40% in controls. The incidence of CMV reactivation at 90\u00a0days was lower in the intervention group (52.00%) compared to controls (77.78%), although not statistically significant (P\u2009=\u20090.580). However, CMV viral loads were significantly lower over time in the intervention group (P\u2009=\u20090.028), suggesting a favorable antiviral effect of CMV-CTLs. Prophylactic infusion of donor-derived CMV-CTLs early after allo-HSCT appears safe and may reduce CMV reactivation and viral burden. These findings support the potential of CMV-CTLs as a novel immunotherapeutic strategy for CMV management in high-risk transplant recipients. Further validation in larger, multicenter trials is warranted.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-27354-6","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:16:44Z","timestamp":1764857804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prophylactic infusion of donor derived CMV specific T cells for the prevention of CMV reactivation following allogeneic HSCT"],"prefix":"10.1038","volume":"15","author":[{"given":"Maryam","family":"Barkhordar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Samareh Salavatipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaz","family":"Bahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Yaghmaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla Sharifi","family":"Aliabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasem","family":"Janbabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Naderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"27354_CR1","doi-asserted-by":"publisher","first-page":"e29525","DOI":"10.1002\/jmv.29525","volume":"96","author":"W Dana Flanders","year":"2024","unstructured":"Dana Flanders, W., Lally, C., Dilley, A. & Diaz-Decaro, J. Estimated cytomegalovirus seroprevalence in the general population of the United States and Canada. J. Med. Virol. 96, e29525. https:\/\/doi.org\/10.1002\/jmv.29525 (2024).","journal-title":"J. Med. Virol."},{"key":"27354_CR2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1172\/JCI45449","volume":"121","author":"M Boeckh","year":"2011","unstructured":"Boeckh, M. & Geballe, A. P. Cytomegalovirus: Pathogen, paradigm, and puzzle. J. Clin. Investig. 121, 1673\u20131680 (2011).","journal-title":"J. Clin. Investig."},{"key":"27354_CR3","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","volume":"71","author":"RF Chemaly","year":"2020","unstructured":"Chemaly, R. F. et al. Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study. Clin. Infect. Dis. 71, 2365\u20132374 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"27354_CR4","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/ijms20112666","volume":"20","author":"S-Y Cho","year":"2019","unstructured":"Cho, S.-Y., Lee, D.-G. & Kim, H.-J. Cytomegalovirus infections after hematopoietic stem cell transplantation: Current status and future immunotherapy. Int. J. Mol. Sci. 20, 2666 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"27354_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","volume":"19","author":"P Griffiths","year":"2021","unstructured":"Griffiths, P. & Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat. Rev. Microbiol. 19, 759\u2013773 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"27354_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbmt.2014.11.002","volume":"21","author":"M Boeckh","year":"2015","unstructured":"Boeckh, M., Murphy, W. J. & Peggs, K. S. Recent advances in cytomegalovirus: An update on pharmacologic and cellular therapies. Biol. Blood Marrow Transplant. 21, 24\u201329 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"27354_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.34172\/apb.2023.046","volume":"13","author":"A Jalili","year":"2023","unstructured":"Jalili, A. et al. Virus-specific T cells: Promising adoptive T cell therapy against infectious diseases following hematopoietic stem cell transplantation. Adv. Pharm. Bull. 13, 469\u2013482. https:\/\/doi.org\/10.34172\/apb.2023.046 (2023).","journal-title":"Adv. Pharm. Bull."},{"key":"27354_CR8","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/cid\/ciz368","volume":"70","author":"X-Y Zhao","year":"2020","unstructured":"Zhao, X.-Y. et al. First-line therapy with donor-derived human cytomegalovirus (HCMV)\u2013specific t cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation. Clin. Infect. Dis. 70, 1429\u20131437 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"27354_CR9","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.bbmt.2018.03.028","volume":"24","author":"P van der Heiden","year":"2018","unstructured":"van der Heiden, P., Marijt, E., Falkenburg, F. & Jedema, I. Control of cytomegalovirus viremia after allogeneic stem cell transplantation: A review on CMV-specific T cell reconstitution. Biol. Blood Marrow Transplant. 24, 1776\u20131782 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"27354_CR10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/nejm199510193331603","volume":"333","author":"EA Walter","year":"1995","unstructured":"Walter, E. A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038\u20131044. https:\/\/doi.org\/10.1056\/nejm199510193331603 (1995).","journal-title":"N. Engl. J. Med."},{"key":"27354_CR11","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","volume":"99","author":"H Einsele","year":"2002","unstructured":"Einsele, H. et al. Infusion of cytomegalovirus (CMV)\u2013specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99, 3916\u20133922. https:\/\/doi.org\/10.1182\/blood.V99.11.3916 (2002).","journal-title":"Blood"},{"key":"27354_CR12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","volume":"362","author":"KS Peggs","year":"2003","unstructured":"Peggs, K. S. et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362, 1375\u20131377 (2003).","journal-title":"Lancet"},{"key":"27354_CR13","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","volume":"116","author":"T Feuchtinger","year":"2010","unstructured":"Feuchtinger, T. et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116, 4360\u20134367. https:\/\/doi.org\/10.1182\/blood-2010-01-262089 (2010).","journal-title":"Blood"},{"key":"27354_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm0596-551","volume":"2","author":"HE Heslop","year":"1996","unstructured":"Heslop, H. E. et al. Long\u2013term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene\u2013modified virus\u2013specific T lymphocytes. Nat. Med. 2, 551\u2013555 (1996).","journal-title":"Nat. Med."},{"key":"27354_CR15","doi-asserted-by":"publisher","first-page":"e2024039","DOI":"10.4084\/mjhid.2024.039","volume":"16","author":"F Herrera","year":"2024","unstructured":"Herrera, F. et al. Letermovir primary cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients: Real-life data from a University Hospital in Argentina. Mediterr. J. Hematol. Infect. Dis. 16, e2024039. https:\/\/doi.org\/10.4084\/mjhid.2024.039 (2024).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"27354_CR16","doi-asserted-by":"publisher","first-page":"740079","DOI":"10.3389\/fonc.2021.740079","volume":"11","author":"M Martino","year":"2021","unstructured":"Martino, M. et al. Letermovir prophylaxis for cytomegalovirus infection in allogeneic stem cell transplantation: A real-world experience. Front. Oncol. 11, 740079. https:\/\/doi.org\/10.3389\/fonc.2021.740079 (2021).","journal-title":"Front. Oncol."},{"key":"27354_CR17","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365. https:\/\/doi.org\/10.1126\/science.aba7365 (2020).","journal-title":"Science"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27354-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27354-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:16:45Z","timestamp":1764857805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27354-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27354"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27354-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial followed CONSORT guidelines and received approval from the Institutional Ethics Committee of Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences (Approval ID: IR.TUMS.HORCSCT.REC.1401.015). Written informed consent was obtained from all participants and\/or their legal guardians prior to study enrollment. No identifying data or images are included in this publication. This trial was registered with the Iranian Registry of Clinical Trials (IRCT20140818018842N30) on 18\/02\/2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"43163"}}